Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) was upgraded by investment analysts at TD Cowen to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.
Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Freedom Capital upgraded Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Canaccord Genuity Group set a $13.00 price objective on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings raised Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.50.
Atara Biotherapeutics Stock Down 2.5%
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.32). The company had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $0.55 million. Atara Biotherapeutics had a negative net margin of 269.42% and a negative return on equity of 79.12%. As a group, equities research analysts anticipate that Atara Biotherapeutics will post -0.16 earnings per share for the current year.
Institutional Investors Weigh In On Atara Biotherapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. Quadrature Capital Ltd lifted its holdings in Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock worth $368,000 after buying an additional 3,779 shares in the last quarter. Bridgeway Capital Management LLC boosted its position in Atara Biotherapeutics by 133.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock valued at $591,000 after buying an additional 18,691 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Atara Biotherapeutics by 28.4% during the fourth quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock valued at $2,689,000 after acquiring an additional 32,836 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Atara Biotherapeutics during the fourth quarter valued at about $220,000. Finally, Renaissance Technologies LLC increased its position in shares of Atara Biotherapeutics by 58.6% during the fourth quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock worth $543,000 after acquiring an additional 11,104 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
Featured Articles
- Five stocks we like better than Atara Biotherapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
